A study of SARS-CoV-2 delta variant breakthrough infections and side effects of the Oxford-AstraZeneca vaccine

• Egile Nagusiak: Nawfal R. Hussein (Egilea), Bizav Naji Rasheed (Egilea), Ibrahim A. Naqid (Egilea), Arshed Mustafa Dirbaz (Egilea), Zana Sidiq M. Saleem (Egilea), Nashwan Ibrahim (Egilea), Dildar H. Musa (Egilea), Sulav Muslih Mohammed (Egilea)
• Formatua: Liburua
• Argitaratua: Elsevier, 2022-12-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Objective: This study aimed to investigate the breakthrough infection rate and safety profile of the AstraZeneca vaccine. Methods: The breakthrough COVID-19 infection rate was defined as a positive polymerase chain reaction test 14 days after the vaccine dose. Safety was assessed as local reactions...